|

Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer

RECRUITINGN/ASponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Actively Recruiting
PhaseN/A
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
Started2023-01-02
Est. completion2025-12-15
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06017557

Summary

PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cyto reduction at the time of Diagnostic laparoscopy.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Patients treated at Fondazione Policlinico Gemelli Hospital, Rome Italy, Trillium -Credit Valley Hospital, Mississauga, Ontario and Princess Margaret Cancer Centre, Toronto, Canada
* Patients fit for cytoreductive surgery
* Patients with a primary diagnosis of suspect Stage III-IV ovarian cancer
* Patients selected for interval cytoreductive surgery after NACT

Exclusion Criteria:

* Patients with pre-operative Stage I-II disease confined to the pelvis
* Patients unfit for surgery
* Lack of information about patients' surgical outcomes and clinicopathological characteristics
* LGSOC, Clear cell and mucinous, non-epithelial histologic subtypes (if available)

Conditions3

CancerOvarian Cancer Stage IIIOvarian Cancer Stage IV

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.